Exploring Natural Compounds for HIV Treatment: A Virtual Screening Study

Background: Bioprospecting for natural compounds has led to the discovery of diverse molecules that have become effective drugs for treating various diseases. However, exploring these compounds remains challenging because of the vast, uncatalogued global biodiversity and the structural complexity of the identified molecules. Virtual screening (VS) has emerged as an effective strategy to support molecular discovery, significantly reducing drug development time and costs. Methods: We virtually screened a natural compound library using quantitative structure-activity relationship (QSAR) models and molecular docking assays, targeting the human immunodeficiency virus (HIV) and its relevant clinical targets. We docked against 11 structures using a single protocol, tested its ability to reproduce a known binding mode by redocking every co-crystallized ligand, and docked each compound alongside 21 established inhibitors of the same sites so predictions could be read against a clinical baseline rather than in isolation. We evaluated the most promising molecules for pharmacokinetic properties and the toxicity of both the parent compounds and their predicted secondary metabolites. Results: In terms of docking score, the compounds identified here do not outperform the approved drugs of the pockets they occupy; what they show is interaction fidelity, the clearest case being a prenylated flavonoid that reproduces the complete interaction fingerprint of nevirapine in the non-nucleoside pocket of reverse transcriptase at a score 1.0 kcal/mol weaker. Conclusions: We present these compounds as scaffolds for optimization rather than candidates for direct testing and report the pockets where our protocol could not be validated so readers do not overinterpret the corresponding predictions.

Authors

Institutions

Publication Details

Journal
Drugs and Drug Candidates
Published
2026-11-13
DOI
https://doi.org/10.3390/ddc5040058
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Exploring Natural Compounds for HIV Treatment: A Virtual Screening Study

Frederico Schmitt Kremer, Daniela Peres Martinez
1 links
Drugs and Drug Candidates
Computational Drug Discovery Methods
article

Exploring Natural Compounds for HIV Treatment: A Virtual Screening Study

Frederico Schmitt Kremer, Daniela Peres Martinez
article en

Abstract

Background: Bioprospecting for natural compounds has led to the discovery of diverse molecules that have become effective drugs for treating various diseases. However, exploring these compounds remains challenging because of the vast, uncatalogued global biodiversity and the structural complexity of the identified molecules. Virtual screening (VS) has emerged as an effective strategy to support molecular discovery, significantly reducing drug development time and costs. Methods: We virtually screened a natural compound library using quantitative structure-activity relationship (QSAR) models and molecular docking assays, targeting the human immunodeficiency virus (HIV) and its relevant clinical targets. We docked against 11 structures using a single protocol, tested its ability to reproduce a known binding mode by redocking every co-crystallized ligand, and docked each compound alongside 21 established inhibitors of the same sites so predictions could be read against a clinical baseline rather than in isolation. We evaluated the most promising molecules for pharmacokinetic properties and the toxicity of both the parent compounds and their predicted secondary metabolites. Results: In terms of docking score, the compounds identified here do not outperform the approved drugs of the pockets they occupy; what they show is interaction fidelity, the clearest case being a prenylated flavonoid that reproduces the complete interaction fingerprint of nevirapine in the non-nucleoside pocket of reverse transcriptase at a score 1.0 kcal/mol weaker. Conclusions: We present these compounds as scaffolds for optimization rather than candidates for direct testing and report the pockets where our protocol could not be validated so readers do not overinterpret the corresponding predictions.

Drugs and Drug CandidatesVol. 5(4)
Universidade Federal de Pelotas (BR)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Good health and well-being
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon